Supersaturated Hydrogen-Rich Water for Outpatients With Persistent Excess Weight
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Hydrogen-rich water, Control.
- Who it may be relevant to
- Registry conditions: Overweight. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Serbia
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Supersaturated Hydrogen-Rich Water for Outpatients With Persistent Excess Weight (HOPE)
Overview
The Supersaturated Hydrogen-Rich Water for Outpatients with Persistent Excess Weight (HOPE) study is a Phase III, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of daily consumption of supersaturated hydrogen-rich water in adults with persistent excess body weight. The trial investigates whether sustained exposure to molecular hydrogen can favorably influence body composition and key metabolic outcomes compared with a placebo water lacking dissolved hydrogen. By enrolling outpatients across multiple centers and applying rigorous blinding and randomization procedures, HOPE aims to generate high-quality clinical evidence on the potential role of hydrogen-rich water as a non-pharmacological, adjunctive strategy for weight management and metabolic health.
Interventions
- Dietary supplement Hydrogen-rich water
Hydrogen-rich water (1.0 L per day) - Dietary supplement Control
Hydrogen-free water (1.0 L per day)
Primary outcome measures
- Apolipoprotein B [Time frame: Change from baseline apolipoprotein B at 6 months]
Secondary outcome measures (3)
- Lipoprotein (a) [Time frame: Change from baseline lipoprotein (a) at 6 months]
- GLP-1 [Time frame: Change from baseline GLP-1 at 6 months]
- Short-chain fatty acids [Time frame: Change from baseline short-chain fatty acids at 6 months]
Eligibility criteria
Inclusion criteria
- Age > 18 years
- Body mass index > 25.0 kg/m2 (persisted for at least six months before screening)
- Stable on their therapy (if any) for ≥ 3 months
- Free of acute disorders and severe chronic diseases
- Informed consent signed
- Normal fasting breath hydrogen levels < 15 ppm
Exclusion criteria
- History of dietary supplement use 4 weeks before the study commences
- Abnormal values for lab clinical chemistry not related with stiyd outcomes (> 2 SD)
- No consent to randomization
- Unwillingness to return for follow-up analysis
- Participation in other clinical trials
- Participants starting or changing major treatments during the study period
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Supportive care
Study locations
Serbia · 1 center
- Center for Health Sciences — Belgrade
Publications
- Todorovic N, Baltic S, Nedeljkovic D, Kuzmanovic J, Korovljev D, Javorac D, Bijelic K, Kladar N, Tarnava A, Ostojic SM. The Effects of 8-Week Hydrogen-Rich Water Consumption on Appetite, Body Composition, Sleep Quality, and Circulating Glucagon-like Peptide-1 in Obese Men and Women (HYDRAPPET): A Randomized Controlled Trial. Medicina (Kaunas). 2025 Jul 18;61(7):1299. doi: 10.3390/medicina61071299. PMID 40731927
- Todorovic N, Kuzmanovic J, Javorac D, Ostojic SM. Role of molecular hydrogen in obesity treatment: modulation of GLP-1, irisin, and PGC-1alpha for improved metabolism. Med Gas Res. 2025 Sep 1;15(3):442-443. doi: 10.4103/mgr.MEDGASRES-D-24-00146. Epub 2025 Feb 7. No abstract available. PMID 40251025
- Korovljev D, Todorovic N, Ranisavljev M, Andjelic B, Kladar N, Stajer V, Ostojic SM. Hydrogen-rich water upregulates fecal propionic acid levels in overweight adults. Nutrition. 2023 Dec;116:112200. doi: 10.1016/j.nut.2023.112200. Epub 2023 Sep 1. No abstract available. PMID 37734117
- Korovljev D, Ostojic J, Todorovic N, Ostojic SM. Molecular hydrogen modulates brain glutamate/GABA-glutamine cycle in overweight humans. Arch Med Sci. 2023 Jul 13;19(4):1151-1153. doi: 10.5114/aoms/162938. eCollection 2023. PMID 37560746
- Todorovic N, Fernandez-Landa J, Santibanez A, Kura B, Stajer V, Korovljev D, Ostojic SM. The Effects of Hydrogen-Rich Water on Blood Lipid Profiles in Clinical Populations: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel). 2023 Jan 18;16(2):142. doi: 10.3390/ph16020142. PMID 37259294
Identifiers
NCT: NCT07410065 · 13012-20-01